受体三阴性乳腺癌的研究进展  

Progression for triple-negative breast cancer

作　　者：蔡铭泉[1] 陈强[2] 施纯枚[2] 

机构地区：[1]福建医科大学附属厦门市第一医院肿瘤内科,福建厦门361000 [2]福建省肿瘤医院内科,350014

出　　处：《临床肿瘤学杂志》2009年第3期283-287,共5页Chinese Clinical Oncology

摘　　要：根据免疫组化染色的特征,将ER、PR和HER2受体均阴性的乳腺癌称之为受体三阴性乳腺癌,三阴性乳腺癌是具有独特生物学及临床特征的乳腺癌亚型,与基底细胞样乳腺癌有较高的一致性,复发早、进展快、生存短。对于三阴性乳腺癌的治疗,目前并没有推荐的化疗方案,而针对三阴性乳腺癌的靶向治疗正在进行临床研究。Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors （ER/PR） and HER2 protein. It is characterized by its unique molecular profiles, aggressive behaviors, distinct risk factors and patterns of recurrence and metastasis, inferior prognosis and lack of targeted therapies. And there is a great deal of overlap between triple-negative and basal-like breast cancer. Therapeutic strategies in the setting of this subtype breast cancer remain a challenge. Several clinical trials on anti-EGFR and antiangiogenesis are ongoing.

关 键 词：乳腺癌 三阴性 基底细胞样 治疗 

分 类 号：R736.8[医药卫生—肿瘤]